Safety of once-or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study

Simple item page
dc.contributor.authorEmren S.V.
dc.contributor.authorZoghi M.
dc.contributor.authorBerilgen R.
dc.contributor.authorÖzdemir İ.H.
dc.contributor.authorÇelik O.
dc.contributor.authorÇetin N.
dc.contributor.authorEnhoş A.
dc.contributor.authorKöseoğlu C.
dc.contributor.authorAkyüz A.
dc.contributor.authorDoğan V.
dc.contributor.authorLevent F.
dc.contributor.authorDereli Y.
dc.contributor.authorDoğan T.
dc.contributor.authorBaşaran Ö.
dc.contributor.authorKaraca I.
dc.contributor.authorKaraca Ö.
dc.contributor.authorOtlu Y.Ö.
dc.contributor.authorÖzmen Ç.
dc.contributor.authorCoşar S.
dc.contributor.authorSümerkan M.
dc.contributor.authorGürsul E.
dc.contributor.authorİnci S.
dc.contributor.authorOnrat E.
dc.contributor.authorErgene O.
dc.date.accessioned2024-07-22T08:10:11Z
dc.date.available2024-07-22T08:10:11Z
dc.date.issued2018
dc.description.abstractOnce-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) may increase patient adherence to treatment but may also be associated with a higher risk of bleeding. In this study, we investigated the adherence to once-or twice-daily dosing of NOACs and the risk of bleeding in nonvalvular atrial fibrillation (NVAF) patients. This multicenter cross-sectional study, conducted between 1 September 2015 and 28 February 2016, included 2214 patients receiving NOACs for at least 3 months, due to NVAF. Patients receiving once-daily or twice-daily NOAC doses were 1:1 propensity score matched for baseline demographic characteristics and the presence of other diseases. The medication adherence was assessed by the 8-item Morisky Medication Adherence Scale. Risk factors were investigated in relation to minor and major bleeding. The mean age of patients was 71 ± 10 years, and 53% of the patients were women. The medication adherence was lower in patients receiving twice-daily NOAC doses compared to once-daily-dose group (47% versus 53%, p = 0.001), and there was no difference between the groups in terms of minor (15% versus 16%, p = 0.292) and major bleeding (3% versus 3%, p = 0.796). Independent risk factors for bleeding were non-adherence to medication (OR: 1.62, 95% CI: 1.23–2.14, p = 0.001), presence of 3 or more other diseases (OR: 10.3, 95% CI: 5.3–20.3, p < 0.001), and HAS-BLED (Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile INR, Elderly, Drugs or alcohol) score (OR: 4.84, 95% CI: 4.04–5.8, p < 0.001). In summary, the once-daily dose of NOACs was associated with increased patient adherence to medication, while it was not associated with bleeding complications. © 2018 ABMSFBIH.
dc.identifier.DOI-ID10.17305/bjbms.2017.2279
dc.identifier.issn15128601
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15121
dc.language.isoEnglish
dc.publisherAssociation of Basic Medical Sciences of FBIH
dc.rightsAll Open Access; Gold Open Access
dc.subjectAdministration, Oral
dc.subjectAged
dc.subjectAnticoagulants
dc.subjectAtrial Fibrillation
dc.subjectCross-Sectional Studies
dc.subjectDabigatran
dc.subjectFemale
dc.subjectHemorrhage
dc.subjectHumans
dc.subjectMale
dc.subjectMedication Adherence
dc.subjectMiddle Aged
dc.subjectPatient Safety
dc.subjectPyrazoles
dc.subjectPyridones
dc.subjectRetrospective Studies
dc.subjectRisk Factors
dc.subjectRivaroxaban
dc.subjectStroke
dc.subjectTurkey
dc.subjectanticoagulant agent
dc.subjectapixaban
dc.subjectdabigatran
dc.subjectpyrazole derivative
dc.subjectpyridone derivative
dc.subjectrivaroxaban
dc.subjectaged
dc.subjectatrial fibrillation
dc.subjectbleeding
dc.subjectcerebrovascular accident
dc.subjectclinical trial
dc.subjectcomplication
dc.subjectcross-sectional study
dc.subjectfemale
dc.subjecthuman
dc.subjectmale
dc.subjectmedication compliance
dc.subjectmiddle aged
dc.subjectmulticenter study
dc.subjectoral drug administration
dc.subjectpatient safety
dc.subjectretrospective study
dc.subjectrisk factor
dc.subjectturkey (bird)
dc.titleSafety of once-or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu